EVOTAZ 300 MG-150 MG TABLET

What it is

EVOTAZ 300 MG-150 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as atazanavir and cobicistat, under the trade name “EVOTAZ”.

FDA gives its dosage form as tablet and its route as oral.

The labeler, the company named on the label, is E.R. Squibb & Sons, L.L.C.

FDA lists it under 2 Established Pharmacologic Classes: Cytochrome P450 3A Inhibitor and Protease Inhibitor.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 00003-3641-11.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $1,561.44 for 30 tablets (30 × $52.0479 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

What NADAC measures · Why 30 tablets · NADAC explanation codes

The NDC

• 00003-3641-11 · E.R. Squibb & Sons, L.L.C. · $52.0479 per EA · eff. 2026-09-23 filed

Compared with its class

Its NADAC price is $52.0479 per EA filed.

Of the 7 other products in FDA’s Cytochrome P450 3A Inhibitor class priced per EA, 4 have a higher middle NADAC price and 3 a lower one. The one in the middle is PREZCOBIX 800 MG-150 MG TABLET, at $79.99382 per EA filed (eff. 2026-09-23).

Of the 11 other products in FDA’s Protease Inhibitor class priced per EA, 3 have a higher middle NADAC price and 8 a lower one. The one in the middle is LOPINAVIR-RITONAVR 200-50 MG TB, at $4.46491 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part D paid $1,593.45 for 30 tablets, at an average of $53.11496 per EA in 2024 (2024-01-01 to 2024-12-31) for “Evotaz” and “Atazanavir Sulfate/Cobicistat”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 6,152 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
• If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.